1Nagaoka T, Morio Y, Casanova N, et al. Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxicrats [ J ]. Am J Physiul Lung Cell Mol Physiol,2004,287(4) :665-672.
2Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension [J]. Circ J,2006,70(2) : 174-178.
3YasudaT, TadaY, TanabeN. etal. Rho-kinase inhibition al- leviates pulmonary hypertension in transgenic mice ex- pressing a domiant-negativetype II bone morphogenetic protein receptor gene [ J ]. Am J Physiol Lung Cell Mol Physio1,2011,301 (5) :667-674.
4Hoffman TM, Wemovsky G, Atz AM, et al. Efficacy and safety of milrinone inpreventing low cardiac output syn- drome in infants and children after corrective surgery for congenital heart di -sease [ J]. Circulation, 2003, 107 (7) :996-1002.
5Felker GM, Benza RL, Chandle AB, et al. Heart failure e- tiology and response to milrinone ind ecomen sated heart failure:results fro m the OPTIME-CHF study [ J ]. J Am Coll Cardiol,2003,41 (6) :997-1003.
6Zhang W,Ke H,Golman RW. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with rr, ilrinone andcilostazol using molecular modeling and site-directed muta- genesis. [J]. Mol1.20(12.62(3) :514-520.
